New research argues drug pricing negotiations would stymie innovation, as Democrats fight for revised proposal
As Democrats hammer out a revised version of their proposal to lower drug prices, new research from the University of Chicago suggests that Medicare negotiations could stymie the development of new cancer drugs — but the size of that effect is widely debated.
Cancer treatments accounted for about 49% of the pipeline making its way through the FDA now, and 27% of new approvals between 2010 and 2019, according to the UC analysis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.